Cull G, Durrant L, Stainer C, Haynes A, Russell N
Department of Haematology, Division of Clinical and Laboratory Sciences, Queensland, Australia.
Br J Haematol. 1999 Dec;107(3):648-55. doi: 10.1046/j.1365-2141.1999.01735.x.
Myeloma cells produce immunoglobulin which is unique to the malignant clone and presents antigenic determinants, or idiotypes, which may function as a tumour-specific antigen. The availability of significant quantities of idiotype protein in the serum makes immunotherapeutic strategies utilizing this protein to generate an anti-idiotype immune response an attractive prospect. We treated two patients with advanced refractory myeloma with a series of four vaccinations using autologous idiotype-protein pulsed dendritic cells combined with adjuvant GM-CSF. The vaccinations were well tolerated with a mild fever post-vaccination in one patient. An idiotype-specific T-cell proliferative response developed in both patients. This T-cell response was associated with the production of gamma-interferon, indicating a TH-1-like response. Furthermore, one patient developed anti-idiotype IgM antibodies. However, no idiotype-specific cytotoxic T-cell response could be demonstrated. Further investigation is warranted to define the optimal conditions for dendritic cell culture and priming to maximize the anti-tumour immune response.
骨髓瘤细胞产生的免疫球蛋白是恶性克隆所特有的,具有抗原决定簇或独特型,可作为肿瘤特异性抗原发挥作用。血清中大量存在独特型蛋白,这使得利用该蛋白产生抗独特型免疫反应的免疫治疗策略成为一个有吸引力的前景。我们对两名晚期难治性骨髓瘤患者进行了一系列四次疫苗接种,使用自体独特型蛋白脉冲树突状细胞联合佐剂GM-CSF。疫苗接种耐受性良好,一名患者接种后出现低热。两名患者均产生了独特型特异性T细胞增殖反应。这种T细胞反应与γ干扰素的产生相关,表明是一种类似TH-1的反应。此外,一名患者产生了抗独特型IgM抗体。然而,未证明有独特型特异性细胞毒性T细胞反应。有必要进行进一步研究以确定树突状细胞培养和启动的最佳条件,以最大限度地增强抗肿瘤免疫反应。